Tavanic 500 Mg - Instructions For Use, Price, Reviews Of Tablets

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2024-01-31 05:02

Tavanik

Tavanik: instructions for use and reviews

1. Release form and composition
2. Pharmacological properties
3. Indications for use
4. Contraindications
5. Method of application and dosage
6. Side effects
7. Overdose
8. Special instructions
9. Use in childhood
10. Drug interactions
11. Analogs
12. Terms and conditions of storage
13. Terms of dispensing from pharmacies
14. Reviews
15. Price in pharmacies

Latin name: Tavanic

ATX code: J01MA12

Active ingredient: levofloxacin (levofloxacin)

Manufacturer: Sanofi-Aventis Deutschland GmbH, Germany

Description and photo update: 2019-13-08

Prices in pharmacies: from 370 rubles.

Buy

Tavanic is an antibacterial agent of the fluoroquinolone group.

Release form and composition

Dosage forms:

film-coated tablets: oblong biconvex shape, with a dividing line on each side, pale yellow-pink color (in blisters: 250 mg - 3, 5, 7 or 10 pcs., 500 mg - 5, 7 or 10 pcs. in a cardboard box 1 blister);
solution for infusion: clear greenish-yellow liquid (100 ml in glass vials without color, in a cardboard box 1 vial).

1 tablet of Tavanic contains:

active substance: levofloxacin hemihydrate - 256.23 mg or 512.46 mg, which is equivalent to 250 mg or 500 mg of levofloxacin;
auxiliary components: hypromellose, crospovidone, microcrystalline cellulose, sodium stearyl fumarate;
the composition of the film shell: macrogol 8000, hypromellose, iron oxide red (E172), titanium dioxide (E171), iron oxide yellow (E172), talc.

1 ml of Tavanic solution contains:

active substance: levofloxacin hemihydrate - 5.1246 mg, which is equivalent to 5 mg of levofloxacin;
auxiliary components: sodium hydroxide, hydrochloric acid, sodium chloride, water for injection.

Pharmacological properties

Pharmacodynamics

Tavanic belongs to synthetic antibacterial drugs of a wide spectrum of action and belongs to the group of fluoroquinolones. Its active ingredient is levofloxacin, which is the levorotatory isomer of ofloxacin. This substance blocks DNA gyrase and topoisomerase IV, prevents the crosslinking of DNA breaks and supercoiling, inhibits DNA synthesis and causes deep morphological changes in the cell membranes of harmful microorganisms, cell walls and cytoplasm. Levofloxacin is active against many strains of microorganisms both in vivo and in vitro.

In vitro, Tavanic is highly susceptible to the following microorganisms (MIC is less than or equal to 2 mg / l, the zone of inhibition is greater than or equal to 77 mm):

anaerobic microorganisms: Veillonella spp., Bacteroides fragilis, Propionibacterium spp., Bifidobacterium spp., Peptostreptococcus, Fusobacterium spp., Clostridium perfringens;
aerobic gram-negative microorganisms: Serratia spp., Serratia marcescens, Acinetobacter spp., Acinetobacter baumannii, Salmonella spp., Actinobacillus actinomycetemcomitans, Pseudomonas spp., Pseudomonas aeruginosa (nosocomial infections caused by this pathogen), Provundcia spp.., Providencia stuartii, Providencia rettgeri, Eikenella corrodens, Proteus vulgaris, Proteus mirabilis, Enterobacter spp., Enterobacter cloacae, Enterobacter aerogenes, Pasteurella spp., Pasteurella multocida, Pasteurella dagmatis, Neonides gummatis, Pasteureseria canis /.png" />
aerobic gram-positive microorganisms: Viridans streptococci peni-S / R (strains sensitive or resistant to penicillin), Bacillus anthracis, Streptococcus pyogenes, Streptococcus pneumoniae peni I / S / R (strains, moderately sensitive, susceptible or resistant to agalptococcus agalptococcus), Streptococci groups G and C, Corynebacterium jeikeium, Corynebacterium diphtheria, Staphylococcus spp. CNS (coagulase-negative), Staphylococcus epidermidis methi-S (methi-susceptible), Staphylococcus aureus methi-S (methicillin susceptible), Staphylococcus coagulase-negative methi-S (I) (coagulase-negative methi-S (I) (coagulase-negative, susceptible to methi-S), Listeria monocytogenes, Enterococcus spp., Enterococcus faecalis;
other microorganisms: Ureaplasma urealyticum, Bartonella spp., Rickettsia spp., Chlamydia trachomatis, Chlamydia psittaci, Chlamydia pneumoniae, Mycoplasma pneumoniae, Mycoplasma hominis, Legionella spp., Legionella pneumophila, Mycobacterium spp.

Moderate sensitivity to levofloxacin (MIC is 4 mg / L, inhibition zone is 16–14 mm) are shown by the following microorganisms:

anaerobic microorganisms: Porphyromonas spp., Prevotella spp.;
aerobic gram-negative microorganisms: Campylobacter coli / jejuni;
aerobic gram-positive microorganisms: Staphylococcus haemolyticus methi-R (methicillin resistant), Staphylococcus epidermidis methi-R (methicillin resistant), Enterococcus faecium, Corynebacterium xerosis, Corynebacterium urealyticum.

Microorganisms showing resistance to levofloxacin (MIC is more than or equal to 8 mg / L, the zone of inhibition is less than or equal to 13 mm) include:

anaerobic microorganisms: Bacteroides thetaiotaomicron;
aerobic gram-negative microorganisms: Alcaligenes xylosoxidans;
aerobic gram-positive microorganisms: Staphylococcus coagulase-negative methi-R (methicillin-resistant coagulase-negative strains), Staphylococcus aureus methi-R (methicillin-resistant strains);
other microorganisms: Mycobacterium avium.

Levofloxacin resistance is the result of a stepwise process of mutations in genes responsible for the encoding of both type II topoisomerases: topoisomerase IV and DNA gyrase. The sensitivity of microorganisms to levofloxacin is also reduced as a result of other mechanisms of resistance formation: the efflux mechanism (intensive elimination of the antimicrobial drug from the microbial cell) and the mechanism of influence on the penetration barriers of the microbe cell (typical for Pseudomonas aeruginosa).

The peculiarities of the mechanism of action of levofloxacin determine the absence of cross-resistance between it and other antimicrobial drugs.

Clinical studies of the effectiveness of Tavanic have proven that it can be used in the treatment of infectious diseases provoked by the following pathogens:

aerobic gram-negative microorganisms: Serratia marcescens, Citrobacter freundii, Pseudomonas aeruginosa, Enterobacter cloacae, Proteus mirabilis, Escherichia coli, Morganella morganii, Haemophilus parainfluenzae, Haemophilus influenza, Moraxella (Branhalmella), catella pneumonia
aerobic gram-positive microorganisms: Streptococcus pyogenes, Streptococcus pneumoniae, Staphylococcus aureus, Enterococcus faecalis;
other microorganisms: Mycoplasma pneumoniae, Legionella pneumophila, Chlamydia pneumoniae.

Pharmacokinetics

After infusion of levofloxacin at a dose of 500 mg for 60 minutes, to healthy volunteers, its maximum plasma concentration was approximately 6.2 μg / ml.

The pharmacokinetics of the active ingredient Tavanic tends to be linear in the range of therapeutic doses of 50–1000 mg. With infusion or ingestion of 500 mg of the drug 1-2 times a day, the equilibrium value of the concentration of levofloxacin is reached within 48 hours.

On the 10th day of intravenous administration of Tavanic at a dosage of 500 mg once a day, the maximum concentration of the active substance is 6.4 + 0.8 μg / ml, and its minimum concentration (content before the administration of the next dose) is 0.6 + 0, 2 μg / ml. On the 10th day of intravenous administration of the drug at a dosage of 500 mg 2 times a day, these indicators were 7.9 + 1.1 μg / ml and 2.3 + 0.5 μg / ml.

Levofloxacin binds to serum proteins by about 30-40%. After a single and repeated administration of 500 mg of Tavanic, the average volume of distribution of levofloxacin is approximately 100 liters, which indicates a high degree of penetration of this substance into the tissues and organ systems of the human body.

After 3 days of administration of 500 mg of Tavanic 1 or 2 times a day, the maximum levels of levofloxacin in the alveolar fluid were observed 2-4 hours after the infusion of the drug and were equal to 4 and 6.7 μg / ml, respectively, with a penetration coefficient of 1 compared with the level substances in blood plasma.

After the introduction into the body, levofloxacin is relatively slowly excreted from the blood plasma (the half-life on average is at least 6-8 hours). More than 85% of the dose taken is excreted in the urine. After a single injection of 500 mg of Tavanic, the total clearance of the substance reached 175 ± 29.2 ml / min.

Levofloxacin is absorbed at a high rate and almost 100% when taken orally, food intake has little effect on the degree of its absorption. Absolute bioavailability when using the drug in the form of tablets is 99-100%. After a single dose of Tavanic 500 mg of the drug, the maximum level of levofloxacin in the blood plasma is achieved within 1-2 hours and is 5.2 + 1.2 μg / ml.

On the 10th day of ingestion of Tavanic at a dosage of 500 mg once a day, the maximum concentration of levofloxacin reached 5.7 + 1.4 μg / ml, and the minimum concentration of the substance was 0.5 + 0.2 μg / ml. On the 10th day of oral administration of the drug in a dosage of 500 mg 2 times a day, these parameters are 7.8 + 1.1 and 3 + 0.9 μg / ml, respectively.

After a single oral administration of 500 mg of levofloxacin, its maximum content in the fluid of the epithelial layer and the bronchial mucosa was reached within 1–4 hours and amounted to 10.8 and 8.3 μg / ml, respectively. At the same time, the coefficients of penetration into the liquid of the epithelial layer and the mucous membrane of the bronchi (compared with the level in the blood plasma) were 0.8–3 and 1.1–1.8, respectively.

After 5 days of oral administration of Tavanic, the average level of levofloxacin 4 hours after the last intake of the drug in the body was 9.94 μg / ml in the epithelial lining fluid and 97.9 μg / ml in alveolar macrophages.

After oral administration of 500 mg of the drug, the maximum content of levofloxacin in the lung tissue was approximately 11.3 μg / g and was recorded 4–6 hours after administration with penetration coefficients of 2–5 compared with the content in blood plasma.

When taken orally for 3 days, 500 mg of Tavanic 1 or 2 times a day, the maximum levels of levofloxacin in the alveolar fluid were observed 2-4 hours after taking the drug and were equal to 4 and 6.7 μg / ml, respectively, with a penetration coefficient of 1 compared with the level of the substance in the blood plasma.

Levofloxacin has a high degree of penetration into cortical and cancellous bone tissue, which also applies to both the distal and proximal femur, with a penetration coefficient (bone tissue / blood plasma) of 0.1–3. The maximum content of the substance in the cancellous bone tissue, localized in the proximal femur, 2 hours after oral administration of 500 mg of Tavanic reached approximately 15.1 μg / g.

Levofloxacin differs by a small degree of penetration into the cerebrospinal fluid.

After oral administration of 500 mg of Tavanic once a day for 3 days, the average concentration of the active ingredient in the prostate tissue was 8.7 μg / g, and the approximate ratio of concentrations in the prostate gland and blood plasma was 1.84.

The approximate concentrations of levofloxacin in urine 8-12 hours after oral administration of Tavanic at a dose of 600, 300 and 150 mg were equal to 162, 91 and 44 μg / ml, respectively.

The substance practically does not participate in metabolic processes (no more than 5% of the administered dose). Its metabolites include levofloxacin N-oxide and demethyl levofloxacin, which are excreted through the kidneys. Levofloxacin is stereochemically stable and resistant to chiral transformations.

After oral administration, levofloxacin is relatively slowly excreted from blood plasma (half-life on average is at least 6-8 hours). More than 85% of the dose taken is excreted in the urine. After a single dose of 500 mg of Tavanic, the total substance clearance reached 175 ± 29.2 ml / min.

When administered intravenously and orally, differences in the pharmacokinetics of levofloxacin have not been registered, therefore, various dosage forms of the drug are interchangeable.

In male and female patients, the pharmacokinetics of levofloxacin remains identical. In older patients, it also remains similar to that in younger patients, excluding differences in creatinine clearance.

With renal dysfunction, the pharmacokinetics of levofloxacin changes. The stronger the renal dysfunction, the lower the renal clearance and the rate of excretion of the substance through the kidneys and the longer the half-life. After a single oral administration of 500 mg of Tavanic, renal clearance and half-life are, respectively:

57 ml / min and 9 hours at CC 50–80 ml / min;
26 ml / min and 27 hours at CC 20–49 ml / min;
13 ml / min and 35 hours with QC less than 20 ml / min.

Indications for use

The use of Tavanic is indicated for the treatment of adult patients with infectious and inflammatory diseases caused by bacteria sensitive to levofloxacin:

community-acquired pneumonia;
chronic prostatitis of bacterial origin;
uncomplicated urinary tract infections;
pyelonephritis and other complicated urinary tract infections;
drug-resistant forms of tuberculosis (as part of complex therapy).

In addition, there are separate indications for each of the Tavanic forms:

tablets: acute form of chronic bronchitis, acute sinusitis, soft tissue and skin infections, treatment and prevention of anthrax when infected by airborne droplets;
solution: septicemia or bacteremia, which has arisen against the background of bacterial infections of the urinary tract and lungs, infections of the abdominal cavity.

Contraindications

epilepsy;
tendon lesions caused by a history of fluoroquinolones;
age up to 18 years;
the period of pregnancy and breastfeeding;
hypersensitivity to quinolones;
individual intolerance to the components of Tavanic.

In addition, tablets are contraindicated for pseudoparalytic myasthenia gravis (myasthenia gravis).

With caution, it is necessary to prescribe Tavanik to patients predisposed to the development of seizures [simultaneous therapy with fenbufen, theophylline and other drugs, the effect of which lowers the threshold of seizure readiness of the brain, the presence of pathologies of the central nervous system (CNS)], with impaired renal function, latent or manifest glucose deficiency -6-phosphate dehydrogenase, electrolyte disturbances (hypokalemia, hypomagnesemia), heart failure, congenital prolongation of the QT interval syndrome, bradycardia, myocardial infarction, diabetes mellitus, with concomitant therapy with drugs that cause prolongation of the QT interval (antiarrhythmic drugs IA and III classes, macrolides, tricyclic antidepressants), with severe neurological adverse reactions to other fluoroquinolones, in elderly patients.

In addition, you should be careful:

tablets: in female patients, with psychosis or a history of mental illness;
solution: with pseudoparalytic myasthenia gravis.

Instructions for use of Tavanik: method and dosage

Pills

Tavanic tablets are taken orally, regardless of food intake, swallowing whole and drinking a sufficient amount of liquid (100-200 ml).

With the simultaneous use of sucralfate, zinc, iron salts, antacids that contain aluminum and / or magnesium, Tavanic is taken no later than 2 hours before or 2 hours after these drugs.

When transferring a patient from parenteral to oral therapy, the dose of the drug is not changed.

The dose and period of treatment is prescribed by the doctor, taking into account the sensitivity of the alleged pathogen, the nature and severity of the course of the disease.

The recommended dosage regimen of Tavanic for patients with normal renal function [creatinine clearance (CC) greater than 50 ml / min]:

community-acquired pneumonia: 500 mg 1-2 times a day, duration of treatment - 7-14 days;
chronic bacterial prostatitis: 500 mg once a day, the course of treatment is 28 days;
uncomplicated urinary tract infections: 250 mg once a day for 3 days;
complicated urinary tract infections: 500 mg once a day for 7-14 days;
pyelonephritis: 500 mg 1 time per day, duration of therapy - 7-10 days;
drug-resistant forms of tuberculosis (as part of complex therapy): 500 mg 1-2 times a day, duration of admission - no more than 90 days;
acute sinusitis: 500 mg once a day, the course of treatment is 10-14 days;
exacerbation of chronic bronchitis: 500 mg 1 time per day for 7-10 days;
anthrax, transmitted by airborne droplets (including prophylaxis): 500 mg once a day, the course of therapy - up to 56 days;
infections of the skin and soft tissues: 500 mg 1-2 times a day for 7-14 days.

Solution for infusion

Tavanik solution is intended for intravenous (IV) drip, slow administration.

The duration of administration of 100 ml (500 mg of levofloxacin) of the drug mixed with 100 ml of infusion solution is at least 60 minutes.

The solution is compatible with 0.9% sodium chloride solution, 2.5% Ringer's solution with dextrose, 5% dextrose solution, combined solutions for parenteral nutrition (carbohydrates, amino acids, electrolytes).

Tavanic solution should not be mixed with sodium bicarbonate solution and other solutions with an alkaline reaction, heparin.

Under room lighting, the bottle with the drug taken out of the cardboard box is suitable for use for no more than 3 days.

The recommended dosage of Tavanic for patients with CC more than 50 ml / min:

community-acquired pneumonia: 500 mg 1-2 times a day, the course of treatment is 7-14 days;
chronic bacterial prostatitis: 500 mg once a day, the course of treatment is 28 days;
uncomplicated urinary tract infections: 250 mg once a day, the course of treatment is 3 days;
pyelonephritis and other complicated urinary tract infections: 250 mg once a day, the course of treatment is 7-10 days. To achieve a clinical effect in severe infections, an increase in a single dose is indicated;
drug-resistant forms of tuberculosis (as part of complex therapy): 500 mg 1-2 times a day, the duration of treatment is up to 90 days;
septicemia or bacteremia: 500 mg 1-2 times a day, the course of treatment is 10-14 days;
infections of the abdominal cavity (in combination with antibacterial drugs that affect the anaerobic flora): 500 mg 1 time per day for 7-14 days.

After reliable eradication of the pathogen or normalization of the patient's body temperature, it is recommended to continue using the drug for at least 2-3 days.

Given the high bioavailability of levofloxacin in the form of tablets, after several days of intravenous drip injection of the solution and with a positive dynamics of therapy, the patient can be transferred to taking the drug orally in the same dose.

In case of impaired renal function (CC 50 ml / min and below), the dosage regimen of tablets and Tavanic solution is adjusted individually, taking into account the CC value and the patient's clinical indications:

CC 50–20 ml / min: the first dose - 250 mg, then - 125 mg once a day; the first dose - 500 mg, then - 250 mg 1 or 2 times a day;
CC 19-10 ml / min: the first dose - 250 mg, then - 125 mg 1 time in 2 days; the first dose - 500 mg, then - 125 mg 1 or 2 times a day;
CC less than 10 ml / min [including continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis]: the first dose - 250 mg, then - 125 mg 1 time in 2 days; the first dose is 500 mg, then 125 mg once a day.

After hemodialysis or CAPD, additional drug intake is not required.

In case of impaired liver function and elderly patients, correction of the dosage regimen of Tavanic is not required.

The patient should not independently violate the dosage regimen prescribed by the doctor, or stop using the drug. If you accidentally skip taking the next dose, it should be taken immediately after remembering, and then continue treatment as directed by the doctor.

Side effects

cardiovascular system: rarely - lowering blood pressure (BP), sinus tachycardia; frequency unknown - prolongation of the QT interval;
nervous system: often - dizziness, headache; infrequently - dysgeusia, drowsiness, tremor; rarely - paresthesia, convulsions; frequency unknown - extrapyramidal disorders, peripheral sensory neuropathy, dyskinesia, peripheral sensory-motor neuropathy, parosmia, loss of taste, loss of smell;
hematopoietic system: infrequently - eosinophilia, leukopenia; rarely - thrombocytopenia, neutropenia; frequency unknown - hemolytic anemia, pancytopenia, agranulocytosis;
mental disorders: often - insomnia; infrequently - confusion of consciousness, feeling of anxiety; rarely - depression, hallucinations, paranoia, agitation, nightmares, sleep disturbances; frequency unknown - behavioral disorders with self-harm (including suicidal thoughts and / or attempts);
hepatobiliary system: often - increased activity of alanine aminotransferase (ALT), aspartate aminotransferase (AST); infrequently - an increase in the concentration of bilirubin in the blood; frequency unknown - severe liver failure, hepatitis, acute liver failure (risk of death, especially with sepsis);
digestive system: often - diarrhea, nausea, vomiting; infrequently - dyspepsia, abdominal pain; frequency unknown - hemorrhagic diarrhea (refers to symptoms of enterocolitis, pseudomembranous colitis, pancreatitis, stomatitis);
organ of vision: very rarely - blurring of the visible image;
organ of hearing and labyrinthine disorders: infrequently - vertigo; rarely - ringing in the ears; frequency unknown - hearing loss;
respiratory system: infrequently - shortness of breath; frequency unknown - allergic pneumonitis, bronchospasm;
immune system: infrequently - urticaria; rarely - angioedema; frequency unknown - anaphylactic and / or anaphylactoid shock;
urinary tract: infrequently - increased serum creatinine concentration; rarely - acute renal failure;
dermatological reactions: infrequently - itching, urticaria, rash; frequency unknown - Stevens-Johnson syndrome, toxic epidermal necrolysis, exudative erythema multiforme, leukocytoclastic vasculitis, photosensitivity;
metabolism: infrequently - anorexia; rarely - hypoglycemia (more often with diabetes mellitus);
musculoskeletal system: infrequently - myalgia, arthralgia; rarely - tendonitis, tendon damage, muscle weakness (especially dangerous with pseudoparalytic myasthenia gravis); frequency unknown - rhabdomyolysis, tendon rupture;
infectious and parasitic diseases: infrequently - resistance of pathogenic microorganisms, fungal infections;
general reactions: infrequently - asthenia; rarely - pyrexia;
others: very rarely - attacks of porphyria (in patients with this pathology);
local reactions: often - reactions at the injection site (hyperemia, soreness).

In addition, taking Tavanic tablets can cause the following side effects:

cardiovascular system: rarely - palpitations; frequency unknown - ventricular tachycardia, ventricular arrhythmias, ventricular tachycardia such as pirouette, cardiac arrest;
nervous system: frequency unknown - benign intracranial hypertension, syncope;
organ of vision: frequency unknown - uveitis, transient loss of vision;
hearing organ and labyrinthine disorders: frequency unknown - hearing loss;
digestive system: infrequently - flatulence, constipation;
hepatobiliary system: often - increased activity of alkaline phosphatase, gamma-glutamyltransferase; frequency unknown - jaundice;
dermatological reactions: infrequently - hyperhidrosis;
musculoskeletal system: frequency unknown - ligament rupture, arthritis, muscle rupture;
metabolism: frequency unknown - hypoglycemic coma, hyperglycemia;
general reactions: the frequency is unknown - pain in the chest, back, extremities.

Overdose

The data obtained as a result of experiments on animals suggests that the most likely signs of an acute overdose of Tavanic are symptoms associated with damage to the central nervous system (convulsions, dizziness, impaired consciousness, including confusion). With the post-marketing use of the drug, when administered in high doses, adverse reactions from the central nervous system have been identified, including hallucinations, convulsions, tremors, and blurred consciousness. Erosive lesions of the gastrointestinal mucosa and nausea are sometimes observed. When conducting clinical and pharmacological studies in which volunteers were injected with doses significantly higher than therapeutic, an increase in the QT interval was noted.

In this case, symptomatic therapy is prescribed. Careful monitoring of the patient's condition is also recommended, including regular ECGs. In case of an acute overdose of the drug in the form of tablets, it is necessary to rinse the stomach and inject antacids, which are protectors of the gastric mucosa. Levofloxacin cannot be removed by any type of dialysis (hemodialysis, peritoneal dialysis, and prolonged peritoneal dialysis). There is no specific antidote.

special instructions

Pseudomonas aeruginosa-induced nosocomial infection may require combination therapy.

Tavanic should be used in accordance with official national guidelines for the appropriate use of antibacterial agents, taking into account the sensitivity of microorganisms in a particular region.

The prescription of the drug should be made on the basis of a diagnosis confirmed by microbiological studies, after isolating the pathogen and establishing its sensitivity to levofloxacin.

It is not recommended to use Tavanic for the treatment of infections of methicillin-resistant strains of Staphylococcus aureus (established or suspected) due to the high probability of their resistance to fluoroquinolones.

During or after therapy, severe diarrhea (including blood) may appear, indicating the development of pseudomembranous colitis caused by Clostridium difficile. In this case, treatment should be stopped immediately and the patient should be given teicoplanin, vancomycin or metronidazole orally. Drugs that inhibit intestinal motility cannot be used.

Tendinitis may appear after two days of therapy and may be bilateral. The danger of the disease is the rupture of the tendons, including the Achilles tendon. The risk group includes elderly patients and patients simultaneously using glucocorticosteroids (GCS). If you suspect the development of tendonitis, Tavanic should be immediately canceled, the affected tendon should be immobilized and its treatment should be started.

Starting with the first doses of Tavanic, hypersensitivity reactions may develop. Since they can be fatal, the use of levofloxacin should be stopped immediately and a doctor should be consulted.

The patient should be informed about the symptoms of liver damage (itching, dark urine, jaundice, abdominal pain), about the obligatory withdrawal of the drug and contacting a doctor if they appear.

During the treatment period and the next two days after the end of therapy, patients are advised to avoid exposure to direct sunlight or artificial ultraviolet radiation.

Due to the high risk of developing superinfection during treatment, it is necessary to re-evaluate the patient's condition.

Elderly patients and female patients are more sensitive to drugs that prolong the QT interval, therefore, special attention should be paid to them when prescribing levofloxacin.

Patients with diabetes mellitus need to closely monitor blood glucose levels.

When symptoms of neuropathy appear, psychotic reactions develop, the drug should be discontinued.

With the development of violations on the part of the organ of vision, it is necessary to seek advice from an ophthalmologist.

Against the background of the use of levofloxacin, laboratory tests of urine for the content of opiates can give a false-positive result, therefore the analysis indicators require confirmation by more specific methods.

Since the drug can inhibit the growth of Mycobacterium tuberculosis, this can further lead to false negative bacteriological results when diagnosing tuberculosis.

During the period of treatment, potentially hazardous activities requiring increased attention and high speed of psychomotor reactions, including driving vehicles and mechanisms, should be avoided.

Pediatric use

According to the instructions, Tavanik is contraindicated in children and adolescents under the age of 18, due to the incomplete growth of the skeleton. Its use increases the risk of damage to the main cartilaginous growth points.

Drug interactions

With the simultaneous use of Tavanic:

calcium salts have a minimal effect on the absorption of the drug in tablet form;
sucralfate significantly weakens the effect of the drug;
warfarin and other indirect anticoagulants can cause an increase in blood coagulation rates (prothrombin time) and / or the development of bleeding, including significant, therefore, it is recommended to regularly monitor blood coagulation;
probenecid, cimetidine disrupt the renal tubular secretion of the drug and slow down the excretion of levofloxacin, but with normal renal function this has no clinically significant effect;
cyclosporine can increase its half-life T _1/2 by 33%, but this does not require dose adjustment;
GCS increase the likelihood of tendon rupture;
digoxin, glibenclamide, ranitidine, warfarin do not have a special effect on the pharmacokinetics of levofloxacin that can affect the clinical effect of the drug.

The combination of levofloxacin with theophylline or fenbufen alone does not significantly affect the effect of the drug. But it should be borne in mind that with combination therapy, which includes several drugs that lower the threshold for seizure readiness of the brain, including theophylline and non-steroidal anti-inflammatory drugs, the risk of a pronounced decrease in the threshold for seizure readiness of the brain increases significantly.

Analogs

Tavanic analogs are: Zolev, Floxium, Lexid, Leflokad, Tigeron, Levobakt, Loxof, Glevo, Leflok, Levobax, Levoflocin, Levocin, Levofloxacin, Levoxa, Levocel, Lebel, Levoflox, Levomak, Levostad, Levoximed, Levotor.

Terms and conditions of storage

Keep out of the reach of children.

Store at temperatures up to 25 ° C, the solution is protected from light.

Shelf life: tablets - 5 years, solution - 3 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews about Tavanik

Reviews of Tavanica among doctors are quite good. This broad-spectrum drug is well tolerated provided that the therapy regimen and general requirements for antibiotics are observed. During the course of treatment, it is recommended to drink a large amount of liquid, eat well (the emphasis on the menu is better on fermented milk products), rest more and take medications to protect the mucous membranes of the gastrointestinal tract.

Patients speak of Tavanic differently. Some patients claim that this is a rather "heavy" drug, which they did not tolerate well during therapy, and also note many side effects. However, many patients praise it for its high efficiency in the fight against diseases provoked by a wide variety of bacteria. Subject to the dosage prescribed by the doctor, the number of adverse reactions is minimized, and only occasionally there is a slight headache and dizziness.

The price of Tavanik in pharmacies

The approximate price for Tavanik in the form of tablets with a dosage of 250 mg is 497–617 rubles (per package including 10 pcs.). You can buy 500 mg Tavanik tablets for 477–522 rubles (for a pack containing 5 tablets) or 915–956 rubles (for a pack containing 10 tablets). The solution for infusion will cost 1000-1077 rubles (for a bottle of 100 ml).

Tavanik: prices in online pharmacies

Drug name

Price

Pharmacy

Tavanic 250 mg film-coated tablets 10 pcs.

370 rbl.

Buy

Tavanic 500 mg film-coated tablets 5 pcs.

399 RUB

Buy

Tavanic 500 mg film-coated tablets 10 pcs.

806 RUB

Buy

Maria Kulkes Medical journalist About the author

Education: First Moscow State Medical University named after I. M. Sechenov, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!